Related Announcements

NOT-MH-21-105 - Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

PA-21-205 - Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)

PAR-20-274 - New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Trial Optional)

RFA-DA-22-040 - High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) RFA-DA-22-040

PAR-20-221 - NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional) PAR-20-221

PAR-20-224 - Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional) PAR-20-224

PAS-21-270 - AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) PAS-21-270

PAR-22-027 - Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) PAR-22-027

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This Notice informs potential applicants of NIDA specific interest areas added to NOT-MH-21-105, "Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure".

The following sections of NOT-MH-21-105 have been modified to reflect participation and NIDA-Specific Interest Area language (changes shown in bold italics):

Issued by

National Institute on Drug Abuse (NIDA)
 

Purpose

The National Institute on Drug Abuse (NIDA) supports research that furthers our mission to advance science on HIV-related consequences of drug use and addiction, and to apply that knowledge to improve individual and public health.

Under this NOSI, NIDA is interested in research on effective health communication for improving HIV-related outcomes, particularly among people who use drugs (PWUD). Areas of particular interest are listed below, but are not limited to:

Developing, testing, and/or tailoring effective communication strategies, materials or campaigns to address topics related to HIV-related outcomes in PWUD such as:

• Reducing stigma directed toward and experienced by PWUD, including intersectional stigma where drug use is a component
• Reducing stigma experienced by providers who contemplate offering services to people who use drugs
• Increasing uptake of services for HIV, drug use and associated comorbidities
• Promotion of emergent clinical approaches, such as long-acting agents for HIV prevention and care among PWUD
• Reducing misinformation regarding HIV, drug use, and their comorbidities, as well as misinformation about preventive and theraputic agents for HIV, harm reduction approaches, and drug use disorder treatments

HIV/drug use intervention and implementation strategies that incorporate testing hypotheses about how different communication approaches effect outcomes:

• Integration of novel communication strategies with existing service delivery approaches such as peer recovery coaches or program outreach
• Provider-patient communication in telehealth or consultation models like Project ECHO and their effects on HIV and/or drug use service uptake and adherence
• Strategies for reaching populations whose access to digital media may be a limited (e.g., lack of wifi) or fragmented (e.g., interruptions in cell service)
• Augmentation of provider or patient/client decision making, with particular attention to neglected considerations such as information complexity, interpersonal or institutional mistrust and potential uncertainty about outcomes
• Testing of emergent social media platforms or communication strategies and/or effective use of multiple platforms (e.g., social media, traditional media, communication through existing channels such as provider education)
• Testing communication approaches related to study recruitment in terms of ability to reach specific audience segments such as users of different substances or clients of different delivery settings (e.g., syringe services vs. drug treatment)
• Testing the efficacy of different communication strategies within prevention or treatment intervention approaches

NIDA has particular interest in communication research that involves relevant audiences (e.g., providers, patients/clients, people who use drugs in the community) throughout the research process, and beyond formative research phases.

Applicants should review the NIDA AIDS Research Program regarding current priorities and current Funding Opportunity Announcements (available on NIDA'swebsite https://www.drugabuse.gov/about-nida/organization/offices/hiv-research-program-hrp), and consult with arelevant Program Officer before submitting an application.

Application and Submission Information

NIDA

This notice is effective immediately and includes receipt dates through May 8, 2024.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice. Applicable funding opportunity announcements include NIH parent announcements listed in NOT-MH-21-105 as well as NIDA specific announcements, including the following or any reissues of these announcements through the expiration date of this notice:

• PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
• PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
• PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
• PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
• PA-21-205 - Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
• PAR-20-274 - New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Trial Optional)
• RFA-DA-22-040 - High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) RFA-DA-22-040
• PAR-20-221 - NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional) PAR-20-221
• PAR-20-224 - Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional) PAR-20-224
• PAS-21-270 - AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) PAS-21-270
• PAR-22-027 - Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) PAR-22-027

All other aspects of NOT-MH-21-105 remain unchanged.

Inquiries

Please direct all inquiries to:

Richard A. Jenkins, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: (301) 443-1923
Email: jenkinsri@nida.nih.gov